Patents by Inventor Robert A. Kastelein

Robert A. Kastelein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancer
    Patent number: 11918648
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: March 5, 2024
    Assignees: MERCK SHARP & DOHME LLC, TRISALUS LIFE SCIENCES, INC.
    Inventors: Ying Yu, Andrew Evan Denker, Svetlana Sadekova, Uyen Truong Phan, Robert A. Kastelein, David Ross Kaufman, Robert L. Coffman, Cristiana Guiducci, Robert S. Janssen
  • COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRINGS
    Publication number: 20240026014
    Abstract: Provided herein are receptor binding proteins that bind to either natural cytokine receptor pairs or non-natural cytokine receptor pairs to create signaling diversity beyond natural receptor pairings.
    Type: Application
    Filed: August 5, 2021
    Publication date: January 25, 2024
    Inventors: Robert Kastelein, Patrick J. Lupardus, Deepti Rokkam
  • Compositions and methods related to IL27 receptor binding
    Patent number: 11873349
    Abstract: Provided herein are IL27R binding proteins that bind to IL27R? and gp130 and comprise an anti-IL27R? VHH antibody and an anti-gp130 VHH antibody.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: January 16, 2024
    Assignee: Synthekine, Inc.
    Inventors: Robert Kastelein, Patrick Lupardus, Deepti Rokkam
  • NAV1.7 BINDERS
    Publication number: 20240002497
    Abstract: Antibodies and antigen-binding fragments thereof that bind the human voltage-gated sodium channel Nav1.7? protein subunit (Nav1.7 binders) are described. In particular embodiments, the Nav1.7 binders comprise a heavy-chain immunoglobulin single variable domain (ISVD or VHH).
    Type: Application
    Filed: November 18, 2021
    Publication date: January 4, 2024
    Applicants: MERCK SHARP & DOHME LLC, MERCK SHARP & DOHME RESEARCH GMBH
    Inventors: Pravien Damitha Abeywickrema, Erik Depla, Bruno Dombrecht, Daniel M. Gorman, Andrea K. Houghton, Robert A. Kastelein, Richard L. Kraus, John Majercak, Kalyan Pande, Sujata Sharma
  • COMPOSITIONS AND METHODS RELATED TO IL27 RECEPTOR BINDING
    Publication number: 20240002542
    Abstract: Provided herein are IL27R binding proteins that bind to IL27R? and gp130 and comprise an anti-IL27R? VHH antibody and an anti-gp130 VHH antibody.
    Type: Application
    Filed: February 3, 2023
    Publication date: January 4, 2024
    Inventors: Robert Kastelein, Patrick Lupardus, Deepti Rokkam
  • IL12RB1-Binding molecules and methods of use
    Patent number: 11859001
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human 1LI2RM, compositions comprising such antibodies, and methods of use thereof.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: January 2, 2024
    Assignee: Synthekine, Inc.
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
  • IL28A RECEPTOR BINDING SYNTHETIC CYTOKINES AND METHODS OF USE
    Publication number: 20230391891
    Abstract: Provided herein are IFNlambdaR1 binding molecules that bind to IL10Rb and IL28RA and comprise an anti-IL28RA sdAb 2 and an anti-IL28RA VHH antibody.
    Type: Application
    Filed: August 5, 2021
    Publication date: December 7, 2023
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus
  • IFNGR1 BINDING MOLECULES AND METHODS OF USE
    Publication number: 20230365696
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IFNgR1, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: November 16, 2023
    Applicant: Synthekine, Inc.
    Inventors: Robert Kastelein, Patrick J. Lupardus, Deepti Rokkam
  • IL12RB2 BINDING MOLECULES AND METHODS OF USE
    Publication number: 20230357414
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL12Rb2, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: November 9, 2023
    Inventors: Sandro Vivona, Robert Kastelein, Deepti Rokkam, Patrick j. Lupardus
  • IL10 RECEPTOR BINDING MOLECULES AND METHODS OF USE
    Publication number: 20230322936
    Abstract: Provided herein are IL10R binding molecules that bind to IL10Ra and IL10Rb and comprise an IL10Rb sdAb and an IL10Rb VHH antibody.
    Type: Application
    Filed: February 3, 2023
    Publication date: October 12, 2023
    Inventors: Robert Kastelein, Mahalakshmi Ramadass, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
  • IL10RB Binding Molecules and Methods of Use
    Publication number: 20230295315
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL10Rb, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: September 21, 2023
    Inventors: Robert Kastelein, Sandro Vivona, Deepti Rokkam, Patrick J. Lupardus
  • IL27RAlpha Binding Molecules and Methods of Use
    Publication number: 20230295314
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL27R?, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: August 4, 2021
    Publication date: September 21, 2023
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
  • IL12 RECEPTOR SYNTHETIC CYTOKINES AND METHODS OF USE
    Publication number: 20230279127
    Abstract: Provided herein are IL12R binding molecules that bind to IL12Rb1 and IL12Rb2 and comprise an anti-IL12Rb2 sdAb and an anti-IL12Rb2 VHH antibody.
    Type: Application
    Filed: August 5, 2021
    Publication date: September 7, 2023
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus
  • IFNGR2 BINDING MOLECULES AND METHODS OF USE
    Publication number: 20230279128
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IFNgR2, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: September 7, 2023
    Applicant: Synthekine, Inc.
    Inventors: Robert Kastelein, Patrick J. Lupardus, Deepti Rokkam
  • IL23 RECEPTOR SYNTHETIC CYTOKINES AND METHODS OF USE
    Publication number: 20230279126
    Abstract: Provided herein are IL23 receptor binding molecules that bind to IL12R?1 and IL23R and comprise an anti-IL23R sdAb and an anti-IL23R VHH antibody.
    Type: Application
    Filed: August 5, 2021
    Publication date: September 7, 2023
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus
  • IL28RA BINDING MOLECULES AND METHODS OF USE
    Publication number: 20230279125
    Abstract: Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL28RA, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: September 7, 2023
    Inventors: Robert Kastelein, Patrick J. Lupardus, Deepti Rokkam
  • IL12RB1-BINDING MOLECULES AND METHODS OF USE
    Publication number: 20230272093
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human 1LI2RM, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: August 31, 2023
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
  • IL2RG BINDING MOLECULES AND METHODS OF USE
    Publication number: 20230272089
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human IL2Rg, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: August 31, 2023
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
  • IL2RB BINDING MOLECULES AND METHODS OF USE
    Publication number: 20230272090
    Abstract: The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of IL2Rb, compositions comprising such antibodies, and methods of use thereof.
    Type: Application
    Filed: August 5, 2021
    Publication date: August 31, 2023
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus, Sandro Vivona
  • IFNGR BINDING SYNTHETIC CYTOKINES AND METHODS OF USE
    Publication number: 20230272088
    Abstract: Provided herein are IFNGR binding molecules that bind to IFNGR1 and IFNGR2 and comprise an anti-IFNGR2 sdAb and an anti-IFNGR2 VHH antibody.
    Type: Application
    Filed: August 5, 2021
    Publication date: August 31, 2023
    Inventors: Robert Kastelein, Deepti Rokkam, Patrick J. Lupardus